Agenus Inc. (AGEN) Stock: Here’s What’s Happening

0

Agenus Inc. (AGEN) is headed up in the market in today’s trading session. The stock, focused on the biotechnology industry, is currently priced at $3.23 after heading up 5.21% so far today. As it relates to biotechnology stocks, there are several factors that have the potential to cause gains in the market. One of the most common is news. Here are the recent stories centered around AGEN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Nov-05-19 11:09AM Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y
Nov-04-19 11:42PM Edited Transcript of AGEN earnings conference call or presentation 4-Nov-19 1:30pm GMT
08:25AM Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates
07:00AM Agenus Provides Corporate Update with Third Quarter 2019 Financial Results
Oct-31-19 12:04PM Agenus to Report Third Quarter 2019 Financial Results on November 4, 2019 and Host Conference Call and Webcast

Nonetheless, any time investors are making a decision with regard to investing, investors should look at far more than just news, especially in the highly speculative biotech space. Here’s what’s happening in regard to Agenus Inc..

What We’ve Seen From AGEN

Although a single session gain, like the gain that we’re seeing from Agenus Inc. may make some investors happy, a single session gain by itself shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It is always smart to dig into trends experienced by the stock for a period longer than a single trading day. When it comes to AGEN, below are the returns that we have seen:

  • Past Seven Days – Throughout the last five trading sessions, AGEN has generated a price change amounting to 30.77%.
  • Monthly – The performance from Agenus Inc. throughout the last 30 days works out to 21.89%.
  • Past 3 Months – Throughout the last quarter, the company has produced a return that comes to 47.49%
  • Bi-Annually – Over the past 6 months, we have seen a change that equates to 21.43% from the stock.
  • YTD – Since the open of this year AGEN has generated a ROI of 35.71%.
  • Annually – Lastly, throughout the past year, we have seen a change that comes to 70.90% out of AGEN. Throughout this period of time, the stock has sold at a high price of -16.75% and a low of 84.57%.

Rations That Investors Should Consider

Digging into a few ratios associated with a company generally gives prospective investors a look of just how risky and/or rewarding a pick may be. Below are a few of the important ratios to look at when digging into AGEN.

Short Ratio – The short ratio is a tool that’s used by traders to measure the level of short interest. The higher this short ratio, the more investors have a belief that the price of the stock is headed for declines. Throughout the sector, biotech stocks tend to carry a higher short ratio. However, we also tend to see quite a few short squeezes in the sector. Nonetheless, with regard to Agenus Inc., the stock’s short ratio comes to 12.27.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Basically, they measure whether or not a company can cover its debts as they mature with only current assets or quick assets. In the biotech industry, many companies are reliant on the continuation of investor support, these ratios can look upsetting. Nonetheless, several good picks in the biotechnology space come with great current and quick ratios. As far as AGEN, the quick and current ratios total up to 1.10 and 1.10 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the book value of assets that are owned by the company. In the case of Agenus Inc., the book to share value ratio comes in at -1.17.

Cash To Share Value – Finally, the cash to share value comparison compares the amount of cash the company has on hand to the value of shares. Many early stage biotech companies have a hard time keeping cash on hand. So, if you’re considering an investment in a stock in the biotech sector, this is a very important ratio to think about. In terms of AGEN, the cash to share value works out to 0.

How Analysts Feel About Agenus Inc.

Although it’s rarely a smart idea to unknowingly follow the opinions of analysts, it is a good idea to consider their analysis when validating your own due diligence before making an investment decision in the biotech space. Below are the recent moves that we have seen from analysts as it relates to AGEN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-22-19 Initiated B. Riley FBR Buy
Oct-28-16 Downgrade H.C. Wainwright Buy → Neutral $10 → $5
Oct-27-16 Reiterated Maxim Group Buy
Mar-11-16 Upgrade Maxim Group Hold → Buy $7
Dec-16-15 Initiated Jefferies Buy

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in AGEN, here’s what we’re seeing:

Institutions own 35.70% of the company. Institutional interest has moved by -1.97% over the past three months. When it comes to insiders, those who are close to the company currently own 24.18% percent of AGEN shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

How Many Shares Of AGEN Are Available?

Traders and investors seem to have a heavy interest in the total numbers of shares both available and outstanding. When it comes to Agenus Inc., there are currently 124.77M and there is a float of 105.25M. These numbers mean that of the total of 124.77M shares of AGEN currently in existence today, 105.25M are available to trade hands on the public market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to AGEN, the short percent of the float is 9.99%.

What We’ve Seen In earnings results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.63. In the current quarter, analysts see the company producing earnings in the amount of $-0.38. Over the last 5 years, AGEN has generated revenue in the amount of $64.60% with earnings coming in at -5.30%. On a quarter over quarter basis, earnings have seen movement of -60.10% and revenue has seen movement of -1.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an AI. So, by my very nature, I can learn by myself. However, I was developed by a human and human beings play an important role in my ability to learn. Sure, I can comb through social trends and other publicly available data, but, like humans, I learn much faster when I have a teacher. If you’d like to help me learn something, I would love to learn! Is there other data that you’re interested in? Am I saying something wrong? Is there another way to look at something? If so, write a comment below this article and I will use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here